These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32115243)

  • 1. Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.
    Li C; Li X; Zhu X; Zhang H; Shen G; Kersey K; Ding Y
    Clin Ther; 2020 Mar; 42(3):448-457. PubMed ID: 32115243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
    Mogalian E; Brainard DM; Osinusi A; Moorehead L; Murray B; Ling KHJ; Perry R; Curtis C; Lawitz E; Lasseter K; Marbury T; Mathias A
    Clin Pharmacokinet; 2018 Nov; 57(11):1449-1457. PubMed ID: 29520729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
    Lawitz E; Landis CS; Flamm SL; Bonacini M; Ortiz-Lasanta G; Huang J; Zhang J; Kirby BJ; De-Oertel S; Hyland RH; Osinusi AO; Brainard DM; Robson R; Maliakkal BJ; Gordon SC; Gane EJ
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):918-926. PubMed ID: 32531259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection.
    Jonas MM; Romero R; Rosenthal P; Lin CH; Verucchi G; Wen J; Balistreri WF; Whitworth S; Bansal S; Leung DH; Narkewicz MR; Gonzalez-Peralta RP; Mangia A; Karnsakul W; Rao GS; Shao J; de Jong J; Parhy B; Osinusi A; Kersey K; Murray KF; Sokal EM; Schwarz KB
    J Pediatr Gastroenterol Nutr; 2024 Jun; 78(6):1342-1354. PubMed ID: 38644678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid bioanalytical LC-MS/MS method for the simultaneous determination of sofosbuvir and velpatasvir in human plasma-application to a pharmacokinetic study in Egyptian volunteers.
    Elkady EF; Aboelwafa AA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Dec; 1102-1103():116-124. PubMed ID: 30384188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in HealthyChineseSubjects.
    Li X; Chen H; Niu J; Chen G; Shen G; Massetto B; Brainard DM; Zhu X; Zhang H; Ding Y
    Clin Ther; 2018 Sep; 40(9):1556-1566. PubMed ID: 30185395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
    PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes.
    Miller MM
    Am J Health Syst Pharm; 2017 Jul; 74(14):1045-1052. PubMed ID: 28687550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
    Mogalian E; Stamm LM; Osinusi A; Brainard DM; Shen G; Ling KHJ; Mathias A
    Clin Infect Dis; 2018 Aug; 67(6):934-940. PubMed ID: 29522076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study.
    Pan C; Chen Y; Chen W; Zhou G; Jin L; Zheng Y; Lin W; Pan Z
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jan; 1008():255-259. PubMed ID: 26684720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C.
    German P; Mathias A; Brainard D; Kearney BP
    Clin Pharmacokinet; 2016 Nov; 55(11):1337-1351. PubMed ID: 27193156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
    Bourgeois S; Horsmans Y; Nevens F; van Vlierberghe H; Moreno C; Beumont M; Vijgen L; van Eygen V; Luo D; Hillewaert V; Van Remoortere P; van de Logt J; Ouwerkerk-Mahadevan S
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.
    Balistreri WF; Murray KF; Rosenthal P; Bansal S; Lin CH; Kersey K; Massetto B; Zhu Y; Kanwar B; German P; Svarovskaia E; Brainard DM; Wen J; Gonzalez-Peralta RP; Jonas MM; Schwarz K
    Hepatology; 2017 Aug; 66(2):371-378. PubMed ID: 27997679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older.
    Tuan J; Okoli A; Ogbuagu O
    Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):881-888. PubMed ID: 38058292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
    Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
    Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Profile of a Generic Formulation of Sofosbuvir and Its Metabolite GS-331007 in Healthy Chinese Subjects.
    Shen Z; Zhu X; Zhang H; Chen H; Niu J; Chen G; Li X; Ding Y
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1073-1080. PubMed ID: 30900816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
    Smith MA; Chan J; Mohammad RA
    Ann Pharmacother; 2015 Mar; 49(3):343-50. PubMed ID: 25515863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
    Murray KF; Balistreri WF; Bansal S; Whitworth S; Evans HM; Gonzalez-Peralta RP; Wen J; Massetto B; Kersey K; Shao J; Garrison KL; Parhy B; Brainard DM; Arnon R; Gillis LA; Jonas MM; Lin CH; Narkewicz MR; Schwarz K; Rosenthal P
    Hepatology; 2018 Dec; 68(6):2158-2166. PubMed ID: 30070726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.
    Asselah T; Shafran SD; Bourgeois S; Lai CL; Mathurin P; Willems B; Nguyen MH; Davis MN; Huang KC; Svarovskaia E; Osinusi A; McNally J; Brainard DM; Shaikh OS; Tran TT
    J Viral Hepat; 2019 Oct; 26(10):1229-1232. PubMed ID: 31216086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.
    Wei L; Lim SG; Xie Q; Văn KN; Piratvisuth T; Huang Y; Wu S; Xu M; Tang H; Cheng J; Le Manh H; Gao Y; Mou Z; Sobhonslidsuk A; Dou X; Thongsawat S; Nan Y; Tan CK; Ning Q; Tee HP; Mao Y; Stamm LM; Lu S; Dvory-Sobol H; Mo H; Brainard DM; Yang YF; Dao L; Wang GQ; Tanwandee T; Hu P; Tangkijvanich P; Zhang L; Gao ZL; Lin F; Le TTP; Shang J; Gong G; Li J; Su M; Duan Z; Mohamed R; Hou JL; Jia J
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):127-134. PubMed ID: 30555048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.